Rithm Capital, Great Ajax Enter a Strategic Transaction
By Stephen Nakrosis
Global asset manager Rithm Capital on Monday said it entered into a strategic transaction with real estate investment trust Great Ajax.
Under the terms of the deal, Great Ajax entered a one-year term loan agreement for up to $70 million with one of Rithm's subsidiaries. Great Ajax said it planned to use borrowings under the term loan and other assets to repay its outstanding convertible notes.
Great Ajax also plans to enter into a management agreement with an affiliate of Rithm to serve as its external manager, the companies said, adding "The transaction will enable Great Ajax to shift its strategic direction and capitalize on commercial real estate investment opportunities."
The deal will also see Great Ajax issue five-year warrants to Rithm, exercisable for shares of Great Ajax's common stock. Also, under a securities purchase agreement, Great Ajax will issue $14 million of its common stock to Rithm.
The closing of the purchase, and other aspects of the deal, are subject to approval by Great Ajax stockholders, the companies said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 26, 2024 18:42 ET (23:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks